clinical trial · NCT05262751
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
Boehringer Ingelheim·phase1·completed·n = 21
HealthyOfev®Nintedanib formulation 1Nintedanib formulation 2
brief summary
The main objective of this trial is to assess single dose drug exposure of several newly developed formulation prototypes of Nintedanib compared to Ofev® following oral administration.
started
Mar 28, 2022
primary completion
Nov 30, 2022
completion
Nov 30, 2022
last updated
May 29, 2024
official title
A Phase I Study for Formulation Selection and Subsequent Optimization of Two Different Oral Formulations of Nintedanib in Healthy Male Subjects (Open-label, Randomised, Single-dose Study in Three Parts)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol